Daniel I Swerdlow

List of Publications by Citations

37 papers	3,591 citations	21 h-index	40 g-index
40 ext. papers	4,501 ext. citations	10.6 avg, IF	3.93 L-index

#	Paper	IF	Citations
37	The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis. *Lancet, The*, **2012**, 379, 1214-24	40	658
36	Mendelian randomization of blood lipids for coronary heart disease. *European Heart Journal*, **2015**, 36, 539-50	9.5	417
35	HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials. *Lancet, The*, **2015**, 385, 351-61	40	409
34	Association between alcohol and cardiovascular disease: Mendelian randomisation analysis based on individual participant data. *BMJ, The*, **2014**, 349, g4164	5.9	406
33	PCSK9 genetic variants and risk of type 2 diabetes: a mendelian randomisation study. *Lancet Diabetes and Endocrinology,the*, **2017**, 5, 97-105	18.1	225
32	Large-scale gene-centric meta-analysis across 32 studies identifies multiple lipid loci. *American Journal of Human Genetics*, **2012**, 91, 823-38	11	189
31	Association of Lipid Fractions With Risks for Coronary Artery Disease and Diabetes. *JAMA Cardiology*, **2016**, 1, 692-9	16.2	168
30	Causal effects of body mass index on cardiometabolic traits and events: a Mendelian randomization analysis. *American Journal of Human Genetics*, **2014**, 94, 198-208	11	156
29	Genome-wide association and Mendelian randomisation analysis provide insights into the pathogenesis of heart failure. *Nature Communications*, **2020**, 11, 163	17.4	140
28	Selecting instruments for Mendelian randomization in the wake of genome-wide association studies. *International Journal of Epidemiology*, **2016**, 45, 1600-1616	7.8	114
27	Interleukin-6 receptor pathways in abdominal aortic aneurysm. *European Heart Journal*, **2013**, 34, 3707-16	9.5	111
26	Plasma urate concentration and risk of coronary heart disease: a Mendelian randomisation analysis. *Lancet Diabetes and Endocrinology,the*, **2016**, 4, 327-36	18.1	100
25	Secretory phospholipase A(2)-IIA and cardiovascular disease: a mendelian randomization study. *Journal of the American College of Cardiology*, **2013**, 62, 1966-1976	15.1	91
24	Genetic Association of Lipids and Lipid Drug Targets With Abdominal Aortic Aneurysm: A Meta-analysis. *JAMA Cardiology*, **2018**, 3, 26-33	16.2	44
23	Image-guided adrenal and renal biopsy. *Techniques in Vascular and Interventional Radiology*, **2010**, 13, 100-9	2.6	43
22	Gene-centric analysis identifies variants associated with interleukin-6 levels and shared pathways with other inflammation markers. *Circulation: Cardiovascular Genetics*, **2013**, 6, 163-70		34
21	Population genomics of cardiometabolic traits: design of the University College London-London School of Hygiene and Tropical Medicine-Edinburgh-Bristol (UCLEB) Consortium. *PLoS ONE*, **2013**, 8, e71345	3.7	33

20	Genetic determinants of circulating interleukin-1 receptor antagonist levels and their association with glycemic traits. *Diabetes*, **2014**, 63, 4343-59	0.9	32
19	Causal relevance of blood lipid fractions in the development of carotid atherosclerosis: Mendelian randomization analysis. *Circulation: Cardiovascular Genetics*, **2013**, 6, 63-72		32
18	Influence of common genetic variation on blood lipid levels, cardiovascular risk, and coronary events in two British prospective cohort studies. *European Heart Journal*, **2013**, 34, 972-81	9.5	28
17	The genetics of coronary heart disease. *British Medical Bulletin*, **2012**, 102, 59-77	5.4	23
16	Characteristics of exhaled particle production in healthy volunteers: possible implications for infectious disease transmission. *F1000Research*, **2013**, 2, 14	3.6	19
15	A dysglycaemic effect of statins in diabetes: relevance to clinical practice?. *Diabetologia*, **2014**, 57, 2433-5	10.3	16
14	Mendelian randomization for studying the effects of perturbing drug targets. *Wellcome Open Research*, **2021**, 6, 16	4.8	15
13	Mendelian Randomization and Type 2 Diabetes. *Cardiovascular Drugs and Therapy*, **2016**, 30, 51-7	3.9	12
12	Mendelian randomization for studying the effects of perturbing drug targets. *Wellcome Open Research*, **2021**, 6, 16	4.8	11
11	Genetic risk factors and Mendelian randomization in cardiovascular disease. *Current Cardiology Reports*, **2015**, 17, 33	4.2	10
10	Treatment and prevention of lipoprotein(a)-mediated cardiovascular disease: the emerging potential of RNA interference therapeutics. *Cardiovascular Research*, **2021**,	9.9	9
9	Harnessing publicly available genetic data to prioritize lipid modifying therapeutic targets for prevention of coronary heart disease based on dysglycemic risk. *Human Genetics*, **2016**, 135, 453-467	6.3	9
8	Phenome-wide association analysis of LDL-cholesterol lowering genetic variants in PCSK9. *BMC Cardiovascular Disorders*, **2019**, 19, 240	2.3	8
7	Genetics of CHD in 2016: Common and rare genetic variants and risk of CHD. *Nature Reviews Cardiology*, **2017**, 14, 73-74	14.8	7
6	Blood Lipids and Type 2 Diabetes Risk: Can Genetics Help Untangle the Web?. *Diabetes*, **2015**, 64, 2344-5	0.9	6
5	Genetic insights into statin-associated diabetes risk. *Current Opinion in Lipidology*, **2016**, 27, 125-30	4.4	6
4	Complex disease genetics: present and future translational applications. *Genome Medicine*, **2009**, 1, 104	14.4	2
3	Abstract 14720: Pre-clinical Safety Assessment of SLN360, a Novel Short Interfering Ribonucleic Acid Targeting LPA. *Circulation*, **2020**, 142,	16.7	1

2	Phenome-wide association analysis of LDL-cholesterol lowering genetic variants in PCSK9	1
1	Mendelian randomisation study for statin treatment - Authorsareply. *Lancet, The*, **2015**, 385, 1946	40